Skip to main content
. 2018 Nov 20;20:141. doi: 10.1186/s13058-018-1067-y

Table 4.

Complete blood counts in patients with circulating tumor cells

No CTC (n = 39) CTC (n = 34) P value Estimate (95% CI)
CA 15-3, mean (SD) 223.71 (384.68) 1084.15 (4136.87) 0.658 6.7 (− 19.2, 87.6)
Alkaline phosphatase, mean (SD) 105.47 (103.98) 198.15 (365.58) 0.401 6 (− 12, 27)
Calcium (korr), mean (SD) 2.34 (0.15) 2.32 (0.25) 0.145 − 0.06 (− 0.13, 0.02)
CRP, mean (SD) 31.92 (47.56) 26.87 (47.69) 0.982 0 (− 8.8, 3.8)
LDH, mean (SD) 281.61 (118.18) 300.15 (228.57) 0.772 − 5 (− 36, 23)
RBC, 1012/L, mean (SD) 4.37 (0.56) 3.85 (0.77) 0.019 − 0.42 (− 0.8, − 0.08)
HGB, g/L, mean (SD) 130.14 (19.85) 118.15 (24.11) 0.051 − 11 (− 21, 0)
HCT, L/L, mean (SD) 0.38 (0.06) 0.35 (0.06) 0.053 − 0.03 (− 0.06, 0)
MCV, fl, mean (SD) 87.46 (5.68) 89.73 (5.26) 0.227 2 (− 1, 4)
MCH, pg, mean (SD) 29.62 (2.52) 30.66 (1.96) 0.157 0.8 (− 0.3, 1.8)
MCHC, g/L, mean (SD) 339.03 (13.98) 341.19 (12.79) 0.667 2 (− 6, 8)
WBC, 109/L, mean (SD) 7.35 (2.13) 7.24 (3.53) 0.334 − 0.6 (− 1.88, 0.81)
Neutrophils, 109/L, mean (SD) 5.33 (1.87) 5.12 (2.87) 0.239 − 0.63 (− 1.65, 0.56)
Lymphocytes, 109/L, mean (SD) 1.37 (0.67) 1.41 (0.85) 0.941 − 0.02 (− 0.38, 0.38)
Monocytes, 109/L, mean (SD) 0.42 (0.12) 0.44 (0.2) 0.843 − 0.01 (− 0.08, 0.07)
Eosinophils, 109/L, mean (SD) 0.16 (0.18) 0.17 (0.12) 0.423 0.02 (− 0.03, 0.09)
Basophils, 109/L, mean (SD) 0.04 (0.07) 0.04 (0.03) 0.256 0.01 (− 0.01, 0.02)
LUC, 109/L, mean (SD) 0.15 (0.22) 0.12 (0.08) 0.912 0 (− 0.03, 0.02)
PLT, 109/L, mean (SD) 289.92 (139.86) 249.93 (91.52) 0.277 − 30 (− 84, 24)
MPV, fl, mean (SD) 8.2 (1.51) 8.68 (1.52) 0.109 0 (0–1)

Abbreviations: CA 15-3 Cancer antigen 15-3, CRP C-reactive protein, HCT Hematocrit, HGB Hemoglobin, LDH Lactate dehydrogenase, LUC Large unstained cells, MCH Mean corpuscular hemoglobin, MCHC Mean corpuscular hemoglobin concentration, MCV Mean corpuscular volume, MPV Mean platelet volume, PLT Platelets, RBC Red blood cells, WBC White blood cells

The table shows complete blood counts in patients with and without circulating tumor cells (CTCs).